International Journal of Breast Cancer / 2018 / Article / Tab 1 / Review Article
Overcoming Therapeutic Resistance of Triple Positive Breast Cancer with CDK4/6 Inhibition Table 1 Pathologic complete response after neoadjuvant chemotherapy in patients with HER2-positive breast cancer stratified by hormonal receptor status.
Clinical trial Chemotherapy and HER2-targeted agents Outcome pCR rate HR+/HER2+ pCR rate HR-/HER2+ Reference NeoSphere Docetaxel Carboplatin Trastuzumab ypT0a 20.0% 36.8% [32 ] NeoSphere Docetaxel Carboplatin Trastuzumab Pertuzumab ypT0 26.0% 63.2% [32 ] NeoALTO Paclitaxel Lapatinib Trastuzumab ypT0 41.6% 61.3% [33 ] NOAH Doxorubicin Paclitaxel Cyclophosphamide Methotrexate Fluorouracil Trastuzumab ypT0 ypN0b 30.0% 51.2% [12 ] ACOSOG Z1041 5-fluorouracil Epirubicin Cyclophosphamide Paclitaxel Trastuzumab ypT0 47.6% 70.4% [34 ]
a –ypT0: pathologic complete response in the breast (absence of invasive neoplastic cells); b –ypN0: pathologic complete response in the axillary lymph nodes (absence of invasive neoplastic cells).